CRL Charles River Laboratories International Inc

Leerink Swann & Company Initiates Coverage of Charles River Laboratories, Inc. (NYSE: CRL) BOSTON, July 14 /PRNewswire/ -- This morning, Biotechnology analyst John Sullivan initiated coverage of Charles River Laboratories with an Outperform rating. About Charles River Laboratories Charles River Laboratories, Inc. (NYSE:CRL) is the world's leading provider of critical research products and integrated preclinical support services for the biomedical community to enable innovative and efficient drug discovery and development. For more than half a century, Charles River has been the global market leader in the commercial production and supply of animal research models for use in the discovery, development, and testing of new pharmaceuticals. Charles River Laboratories is headquartered in Wilmington, Massachusetts. About Leerink Swann & Company Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Health Care Facilities, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2003 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp is comprised of almost 10,000 consultants who are practicing physicians, surgeons, and biomedical professionals. Leerink Swann & Company is a member NASD/SIPC. Leerink Swann & Company is a member of the National Association of Securities Dealers, CRD number 39011. Contact: John I. Fitzgerald Leerink Swann & Company (617) 918-4564 http://www.leerink.com/ DATASOURCE: Leerink Swann & Company CONTACT: John I. Fitzgerald of Leerink Swann & Company, +1-617-918-4564 Web Site: http://www.leerink.com/

Copyright